Plain-English translation of NCT07119463 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing albumin infusion—a treatment that replaces a blood protein that often drops after stomach cancer surgery—to see if keeping it at higher levels reduces serious complications. The study compares two approaches: starting treatment when albumin drops below 25 g/L (lower threshold) versus starting at 30 g/L (higher threshold). The goal is to find the best albumin management strategy for patients recovering from gastric cancer surgery.
After gastric cancer surgery, patients often develop low albumin levels, which can slow recovery and lead to serious complications like infections and poor wound healing. This trial aims to determine the best albumin target level to prevent these problems and help patients recover faster.
You likely qualify if…
You likely don't qualify if…
After your gastric cancer surgery, you will be placed into one of two groups based on study design. Your albumin blood levels will be monitored closely during your hospital stay. If your albumin drops below your group's threshold (either 25 g/L or 30 g/L), you will receive albumin infusions to bring it back up. The study team will track your recovery for 30 days after surgery, measuring your albumin levels, how quickly your digestive system recovers, how long you stay in the hospital, and any complications that develop.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China